A new study from Uganda provides the first evidence to date that resistance to a lifesaving malaria drug may be emerging in the group of patients that accounts for most of the world’s malaria deaths.
The study, presented Friday at the Annual Meeting of the American Society of Tropical Medicine and Hygiene and published in the Journal of the American Medical Association (JAMA), documented partial resistance to the malaria drug artemisinin in 11 of 100 children, ages 6 months to 12 years.
It was gathered that young African children suffering from severe infections were being treated for “complicated” malaria, that is, malaria with signs of severe disease caused by the malaria parasite Plasmodium falciparum.
Also, 10 patients who were thought to have been cured suffered a repeat malaria attack within 28 days from the same strain of malaria that caused the original infection, suggesting that the initial treatment did not entirely kill the infecting parasites.
“This is the first study from Africa showing that children with malaria and clear signs of severe disease are experiencing at least partial resistance to artemisinin,” said Chandy John, MD, MS, director of the Indiana University School of Medicine Ryan White Center for Infectious Diseases and Global Health, who is a co-author of the study along with colleagues Ruth Namazzi and Robert Opoka from Makerere University in Kampala in Uganda, Ryan Henrici from University of Pennsylvania, and Colin Sutherland from London School of Hygiene & Tropical Medicine.
John, a former ASTMH president, said, “It’s also the first study showing a high rate of African children with severe malaria experiencing a subsequent malaria episode with the same strain within 28 days of standard treatment with artesunate, a derivative of artemisinin, and an artemisinin combination therapy (ACT).”
The arrival of artemisinin therapies some 20 years ago was a significant advance in the global fight against malaria due to their power to rapidly cure infections and because malaria parasites had developed resistance to other drugs. In 2008, reports from Cambodia noted partial artemisinin resistance.
By 2013, there was evidence that in some patients, the drug was utterly failing. In the last few years, there has been increasing evidence that artemisinin resistance has now spread from that region into East Africa. The prospect of artemisinin losing its efficacy is particularly alarming for Africa and especially for African children. The region accounts for 95% of the 608,000 people who die from malaria each year, and a large majority of malaria deaths in Africa are children under 5.
While all of the children in the study eventually recovered, 10 were infected with malaria parasites that harbour genetic mutations linked to artemisinin resistance in Southeast Asia.
The study noted that while these mutations have been documented in Africa in less severe cases, this was the first time they have been seen in parasites causing complicated malaria in hospitalised African children. The term “complicated” malaria is used to define cases where the disease is at risk of causing potentially life-threatening complications, like severe anaemia or brain-related problems known as cerebral malaria.
John said that researchers classified patients as suffering from partial resistance based on the World Health Organization’s defined half-life cutoff for parasite clearance of more than five hours, meaning requiring more than five hours to reduce a patient’s parasite burden by 50%.
Two children required longer than the standard maximum of three days of artesunate therapy because they failed to clear their parasites with three days of therapy. He said longer treatment times increase the risk of poor outcomes. Also, he said that in Southeast Asia, the path to broadly resistant malaria parasites started with evidence of partial artemisinin resistance, and the concern is that the pattern will be repeated in sub-Saharan Africa.
The Ugandan children in the study received what is considered the gold standard for treating complicated malaria infections: an intravenous infusion of artesunate followed by oral treatment with an ACT that combines another derivative of artemisinin, artemether, with the malaria drug lumefantrine.
John said the relatively high number of recurrent cases raises concerns that the efficacy of lumefantrine may also be declining. The drug is paired with artemether to make it harder for parasites to develop artemisinin resistance and because lumefantrine stays in the body longer than artemether. Therefore, it can kill any remaining parasites not cleared by the shorter-acting artemisinin.
John said the study emerged from ongoing work in Uganda investigating the outcomes of children who experience episodes of severe malaria. He said researchers pivoted to a focus on drug resistance because they noticed some children appeared to be slower to respond to the infusion of artesunate followed by an oral ACT.
“The fact that we started seeing evidence of drug resistance before we even started specifically looking for it is a troubling sign,” John said. “We were further surprised that, after we turned our focus to resistance, we also found patients who had recurrence after we thought they had been cured.”
